ClinicalTrials.gg
RecruitingNCT07068620SHIVA-CogNeuroUpdated Feb 2, 2026

Neurophysiological and Behavioral Study of the Cognitive Deficits Associated With Cerebral Small Vessel Disease in the SHIVA Cohort. SHIVA-CogNeurophys

An interventional study of Home-based cognitive training in Cerebral Small Vessel Disease, Stroke and Cognitive Complaint, sponsored by University Hospital, Bordeaux. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-02.

Sponsored by University Hospital, Bordeaux · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Cerebral small vessel disease (cSVD) is characterized by an alteration of the structure and function of small penetrating brain arteries. Highly prevalent in older individuals from the general population, it represents a leading cause of stroke and a major contributor to cognitive decline and risk of dementia.

Better detection and management of covert cSVD would have a major impact on preventing disability and costs related to stroke, cognitive impairment and dementia. The aim of the present study is to identify novel electroencephalographic (EEG) biomarkers of the cognitive deficits associated with cSVD, and how these biomarkers and cognitive performance are affected by personalized cognitive training or transcranial alternating current stimulation (tACS), a non-invasvie brain stimulation technique.

Read the detailed description

cSVD is by far the most prevalent vascular contributor to cognitive impairment in the population. However, accurate quantitative estimates of the predictive ability of cSVD for risk of dementia are lacking. Moreover, stratification of cognitive decline and risk of dementia in cSVD patients according to imaging characteristics as well as evidence of coexisting neurodegenerative disease and vascular comorbidity are lacking. Moreover, there is currently no specific mechanism-based treatment, leading to empirical and heterogeneous clinical practice, which in most instances consists of ignoring these lesions. This clinical blind spot represents a major "missed opportunity" for the prevention of cognitive decline and dementia.

This study aims to explore the electroencephalographic (EEG) characteristics of patients with either extensive or minimal neurovascular lesions due to cSVD in 80 patients above 60 years old. The main goal is to identify EEG biomarkers that characterize these lesions and the associated cognitive deficits. Secondary objectives aim to assess the potential impact of cognitive training paradigms and non-invasive brain stimulation (namely transcranial alternating current stimulation - tACS) on these biomarkers and on cognitive performance.

Participants will be divided into two groups. The first group will consist of patients with no or minor white matter hyperintensities on brain MRI (i.e. features of minor cSVD) , while the second group will include patients with moderate to severe white matter hyperintensities (i.e., features of extensive cSVD).

This exploratory study leverages the uniqueness of the SHIVA cohort, a deeply characterized resource for investigation of cSVD. To our knowledge, the combination of EEG recordings, cognitive training, and noninvasive brain stimulation in cSVD patients is entirely novel

02

Conditions studied

  • Cerebral Small Vessel Disease
  • Stroke
  • Cognitive Complaint

Keywords

  • Cognitive decline
  • dementia
  • stroke
  • small vessel disease
  • healthy brain aging
  • electroencephalography
  • neuromodulation
  • transcranial alternating current stimulation
  • cognitive training
  • cognitive rehabilitation
03

In context

Cerebral Small Vessel Diseases

128 studies on the registry are indexed under Cerebral Small Vessel Diseases; 71 are open to participants now.

This study's planned enrollment of 80 is close to the median of 86 across 72 interventional studies indexed under Cerebral Small Vessel Diseases.

Browse Cerebral Small Vessel Diseases studies →

Lead sponsor

University Hospital, Bordeaux is the lead sponsor of 807 studies on the registry; 198 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients included or previously included in the SHIVA cohort
  • Basic computer skills (ability to open a browser, use a mouse and keyboard)
  • Access to a personal computer with an internet connection
  • Independent in Activities of Daily Living (ADL) with a score ≥ 5/6, and in Instrumental Activities of Daily Living (IADL) with a score ≥ 4/8
  • Informed and written consent signed by the participant and the investigating physician for this study

Exclusion criteria

Exclusion Criteria:

  • Motor impairments preventing the use of a keyboard and mouse (e.g., motor issues related to severe hand osteoarthritis)
  • Depressive symptoms indicated by a score of 2 to 4 on the mini Geriatric Depression Scale (mini GDS), which includes 4 items
  • Age-related macular degeneration (AMD)
  • Untreated glaucoma
  • Untreated psychiatric conditions that interfere with cognitive assessments
  • Diagnosed attention deficit disorder with or without hyperactivity or patients who could not complete all cognitive tests required in the SHIVA cohort
  • Systemic diseases that cause cognitive changes, such as obesity and metabolic disorders
  • History of epilepsy or seizures
  • Scalp sensitivity or skin lesions (dermatitis, wounds, etc.)

for the use of electrical stimulation:

  • Surgical clips, metal sutures, staples, stents
  • Osteosynthesis material in the head or neck
  • Pacemaker
  • Implanted hearing aid
  • Ocular foreign bodies, shrapnel, bullets
  • Metalworker
  • Pacemaker or neurostimulator
  • Heart valve or endovascular material
  • Ventricular shunt valve

    • Recent exposure (\< 6 months) to brain stimulation (tDCS, TMS, etc.)
    • Ongoing participation in a clinical trial or cognitive training program
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Personalized cognitive training using an AI algorithmwith a non-linear learning path adapted to each

    Personalized cognitive training using an AI algorithm (zone of proximal development and empirical success - ZPDES - multi-arm algorithm), with a non-linear learning path adapted to each participant.

    Device: Home-based cognitive training

  • Active comparator
    Traditional cognitive training

    Traditional cognitive training using a "staircase" method, featuring a linear progression.

    Device: Home-based cognitive training

Interventions

  • DeviceHome-based cognitive training

    All interventions will be carried out for both groups of participants, with either minimal or extensive cSVD. Upon enrollment, each participant will undergo two hospital visits (visit 1 at day 0, visit 2 at day 7), followed by a home-based cognitive training across 10 days (days 15-24), two more hospital visits (visit 3 at day 26, visit 4 at day 33), and finally a follow-up cognitive testing at home after 6 months.

06

What researchers measure

Primary outcomes

  1. EEG signal power

    The primary outcome measure is the average EEG signal power (across different frequency bands and for various electrodes) between the two participant groups with either minor or extensive cSVD

    Time frame: Day 0, Day 26, Day 33

07

Study locations

1 of 1 sites recruiting
  • CHU de Bordeaux, Hôpital Pellegrin, Unité Neurovasculaire
    Bordeaux, 33000, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2025 (actual). Primary completion is estimated for Mar 2028, 31 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2025
First posted
Jul 16, 2025
StartActual
Aug 7, 2025
Primary completionEst.
Mar 7, 2028
CompletionEst.
Mar 7, 2028
Last update
Feb 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07068620
Responsible party
Sponsor
First posted
Jul 16, 2025
Start date
Aug 7, 2025
Primary completion
Mar 7, 2028 (estimated)
Completion
Mar 7, 2028 (estimated)
Last update
Feb 2, 2026

Study contacts

IGOR SIBON, MD, PhD
Contact
igor.sibon@chu-bordeaux.fr
0556795313 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion